Apollomics Inc. (NASDAQ:APLM) Sees Significant Decrease in Short Interest

Apollomics Inc. (NASDAQ:APLM) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 12,471 shares, a drop of 15.2% from the February 12th total of 14,705 shares. Based on an average trading volume of 5,401 shares, the short-interest ratio is currently 2.3 days. Approximately 1.1% of the company’s stock are short sold. Approximately 1.1% of the company’s stock are short sold. Based on an average trading volume of 5,401 shares, the short-interest ratio is currently 2.3 days.

Apollomics Trading Up 0.5%

APLM opened at $19.90 on Monday. The business’s 50-day simple moving average is $19.96 and its 200-day simple moving average is $17.73. Apollomics has a one year low of $3.66 and a one year high of $42.12.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apollomics in a report on Monday, December 29th. Wall Street Zen upgraded shares of Apollomics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Apollomics currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new position in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent SEC filing. 19.13% of the stock is owned by institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.